What is retroperitoneal lymph‑node dissection (RPLND) in the management of non‑seminomatous germ‑cell tumor (NSGCT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is RPLND in Non-Seminomatous Germ Cell Tumor?

Retroperitoneal lymph node dissection (RPLND) is a surgical procedure that removes lymph nodes from the retroperitoneum and serves as both a diagnostic staging tool and definitive treatment for non-seminomatous germ cell tumors (NSGCT), with bilateral nerve-sparing RPLND being the standard surgical approach. 1

Role and Indications

RPLND functions in three distinct clinical scenarios for NSGCT:

Primary RPLND (Stage I-IIA)

  • Stage I NSGCT: Primary nerve-sparing RPLND is an alternative to surveillance or adjuvant chemotherapy, though it should only be considered when contraindications to chemotherapy exist 2
  • Stage IIA marker-negative: Nerve-sparing RPLND serves both diagnostic and therapeutic purposes, particularly when a single progressing lymph node suggests teratoma 2
  • Achieves cure in up to 90% of patients with low-volume retroperitoneal disease 3

Post-Chemotherapy RPLND (Most Common Indication)

Resection is mandatory for all patients with residual masses >1 cm in greatest diameter after chemotherapy completion 1. This is the most critical indication because:

  • No diagnostic tool or risk calculator can accurately predict histology of residual masses 1
  • Surgery should be performed within 6-8 weeks after the last chemotherapy cycle 1
  • For residual masses <1 cm, the role is uncertain with relapse risk of 6-9%; close surveillance is an alternative 1
  • After salvage chemotherapy or high-dose chemotherapy, surgery is indicated even for masses <1 cm due to higher risk of active disease 1

Histological Findings and Their Implications

Post-chemotherapy RPLND reveals three possible histologies with vastly different prognoses 4, 5:

  • Post-pubertal teratoma (32-63%): Best outcomes with 96% 5-year overall survival and 77% relapse-free survival 4
  • Viable germ cell tumor (7-48%): Requires consideration of adjuvant chemotherapy
  • Fibrosis/necrosis (11%): Associated with worse relapse-free survival 4
  • Somatic malignancy (8%): Poorest prognosis 4

Surgical Technique

Bilateral nerve-sparing RPLND is the standard surgical approach 1. Key technical considerations:

  • Template selection: Ipsilateral template resection may be considered for residual masses <5 cm with unilateral disease on pre- and post-chemotherapy CT 1
  • Nerve preservation: Critical for maintaining ejaculatory function
  • Minimally invasive approaches: Laparoscopic or robotic RPLND may yield comparable outcomes in selected cases with low-volume disease when performed by very experienced surgeons, though long-term data verifying comparability with open surgery are lacking 1, 6

Critical Pitfalls

The inability to reliably exclude teratoma or viable germ cell cancer mandates post-chemotherapy RPLND for all NSGCT patients with residual masses >1 cm 3. The high rate of teratoma (up to 63%) in contemporary series underscores the ongoing need for surgical resection 5.

Residual seminoma masses require different management: Initial monitoring via imaging and tumor markers, with PET imaging for masses >3 cm performed at least 2 months post-chemotherapy to avoid false-positives 1.

Outcomes and Treatment Burden

For pathological stage II disease after primary RPLND 7:

  • 5-year relapse-free survival: 72% with RPLND alone vs 92% with RPLND plus adjuvant chemotherapy
  • Disease-specific survival: 98% vs 100% (not statistically different)
  • Only 25% of patients in the RPLND-only group required subsequent chemotherapy, suggesting adjuvant chemotherapy may constitute overtreatment for most patients

Larger residual mass size correlates with higher relapse risk and increased probability of somatic malignancy 4, making complete surgical resection at experienced centers essential.

Center Expertise Requirement

RPLND should be performed at referral centers by high-volume surgeons 1, 2, particularly for:

  • Residual seminoma masses (intense fibrosis makes removal difficult) 1
  • Bilateral template dissections
  • Marker-positive salvage cases 4

Complication rates at experienced centers are acceptable, with grade III-IV complications considered rare (approximately 9% in contemporary series) 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.